CORE 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
- Stadium
- klaar
- Middel
- Olezarsen (ISIS 678354)
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 14 juni 2023
- Last Patient In
- 10 juni 2024
- Last Patient Last Visit
- 15 oktober 2025
National Lead
prof. dr. E.S.G. Stroes
Cardioloog
Studiedirecteur
drs. K.W. Wu
Cardioloog
Contact Kantoor
